Table 4.

Correlation of SF-12 scores according to demographic and clinical factors. Significant p levels (<0.05) are in bold.

	n	PCS Median (IQR)	p	n	MCS Median (IQR)	p
Total	337	46.6 (39.1–53.5)		337	53.2 (47.1–57.9)
Sex			0.077			0. 012*
Male	244	46.9 (40.8–54.0)		244	53.5 (47.8–58.0)
Female	93	43.5 (35.8–52.7)		93	52.2 (42.1–57.0)
Age			0.140			0.644
≤ 40	18	36.8 (34.2–50.2)		18	53.6 (45.6–60.3)
41–50	27	46.9 (39.4–55.2)		27	53.7 (43.6–58.4)
51–60	79	47.1 (42.4–54.8)		79	53.4 (49.6–57.9)
61–70	117	45.9 (39.1–53.4)		117	52.9 (46.7–57.8)
> 70	96	46.4 (37.9–52.2)		96	53.3 (45.2–57.7)
Cirrhosis			0.807			0.539
Yes	123	46.6 (40.2–52.3)		123	53.4 (47.8–58.3)
No	211	46.8 (38.9–54.6)		211	53.2 (46.5–57.8)
Tumor type			0.331			0.538
HCC	145	47.0 (41.7–54.2)		45	52.9 (47.1–57.9)
CCC	25	42.2 (36.8–55.5)		6	54.7 (46.2–57.9)
Metastases	159	45.9 (38.1–53.4)		58	53.4 (47.1–57.8)
Benign	7	37.1 (34.3–48.4)		7	51.0 (40.7–60.2)
Tumor size			0.191			0.680
< 3 cm	182	46.9 (41.4–53.4)		182	53.5 (47.1–57.8)
> 3 cm	151	44.3 (37.7–54.1)		151	52.7 (46.4–58.1)
Tumor number			0.315			0.390
n = 1	182	46.9 (40.7–53.5)		182	53.7 (47.2–58.1)
n > 1	152	44.3 (38.1–54.5)		152	52.8 (47.0–57.8)
Pain after RFA			0.000*			0.090
Present	180	43.2 (36.2–50.7)		180	52.5 (45.7–57.5)
Absent	157	48.6 (42.6–55.3)		157	54.0 (48.5–58.1)
Complications			0.005*			0.317
Present	29	40.6 (33.1–47.5)		29	49.6 (40.2–60.1)
Absent	307	46.9 (40.0–54.6)		307	53.3 (47.2–57.8)
Redo RFA			0.009*			0.011*
Yes	330	46.9 (39.5–53.5)		330	53.3 (47.2–57.9)
No	7	32.8 (30.2–39.2)		7	42.6 (38.8–50.8)

PCS physical component summary, MCS mental component summary, HCC hepatocellular carcinoma, CCC cholangiocellular carcinoma.